About Novus Diagnostics

Novus Diagnostics is developing a sample-to-answer sepsis diagnostic device that utilizes patented microfluidic electrochemical sensors and advanced diagnostic algorithms to deliver accurate results within 15 minutes. This rapid bedside test enables clinicians to confirm infections and classify pathogens, facilitating immediate targeted treatment during critical early stages of sepsis.

```xml <problem> Sepsis, a bloodstream infection, requires rapid diagnosis and targeted treatment to improve patient outcomes, as delays can be fatal. Traditional sepsis diagnosis often involves lengthy lab procedures, hindering timely clinical decision-making during the critical early stages of the condition. </problem> <solution> Novus Diagnostics offers a rapid, point-of-care diagnostic solution for sepsis that delivers accurate results in 15 minutes. The SepTec™ platform utilizes patented microfluidic electrochemical sensors and advanced diagnostic algorithms to simultaneously diagnose infection and classify the causative pathogen (Gram-negative, Gram-positive, or fungal). This enables clinicians to confirm infections and initiate targeted treatment during the critical early stages of sepsis, directly at the patient's bedside. </solution> <features> - Sample-to-answer sepsis diagnostic device providing results in 15 minutes - Patented microfluidic electrochemical sensors for pathogen detection - Advanced diagnostic algorithms for accurate result interpretation - Simultaneous diagnosis of infection and classification of the causative pathogen (Gram-negative, Gram-positive, or fungal) - Point-of-care testing, enabling rapid bedside assessment </features> <target_audience> The primary target audience includes clinicians and healthcare providers in acute care settings, such as hospitals and emergency departments, who require rapid and accurate sepsis diagnosis to facilitate timely treatment decisions. </target_audience> ```

What does Novus Diagnostics do?

Where is Novus Diagnostics located?

Novus Diagnostics is based in Dublin, Ireland.

When was Novus Diagnostics founded?

Novus Diagnostics was founded in 2020.

How much funding has Novus Diagnostics raised?

Novus Diagnostics has raised 9730000.

Location

Dublin, Ireland

Founded

2020

Funding

9730000

Employees

19 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Novus Diagnostics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

novus-dx.com 2K+

Crunchbase

Founded 2020 – Dublin, Ireland

Funding

Estimated Funding

$5M+

Team (15+)

No team information available.

Company Description

Problem

Sepsis, a bloodstream infection, requires rapid diagnosis and targeted treatment to improve patient outcomes, as delays can be fatal. Traditional sepsis diagnosis often involves lengthy lab procedures, hindering timely clinical decision-making during the critical early stages of the condition.

Solution

Novus Diagnostics offers a rapid, point-of-care diagnostic solution for sepsis that delivers accurate results in 15 minutes. The SepTec™ platform utilizes patented microfluidic electrochemical sensors and advanced diagnostic algorithms to simultaneously diagnose infection and classify the causative pathogen (Gram-negative, Gram-positive, or fungal). This enables clinicians to confirm infections and initiate targeted treatment during the critical early stages of sepsis, directly at the patient's bedside.

Features

Sample-to-answer sepsis diagnostic device providing results in 15 minutes

Patented microfluidic electrochemical sensors for pathogen detection

Advanced diagnostic algorithms for accurate result interpretation

Simultaneous diagnosis of infection and classification of the causative pathogen (Gram-negative, Gram-positive, or fungal)

Point-of-care testing, enabling rapid bedside assessment

Target Audience

The primary target audience includes clinicians and healthcare providers in acute care settings, such as hospitals and emergency departments, who require rapid and accurate sepsis diagnosis to facilitate timely treatment decisions.